Therapeutic potential of anti-inflammatory drugs in focal stroke

Expert Opinion on Investigational Drugs

Volumn 9, Issue 10, 2000, Pages 2281-2306

  Barone, F C ^a   Parsons, A A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adhesion molecules; Chemokines; Closed head injury; Cytokine suppressive anti inflammatory drugs; Gene expression; IL 1 ; Inflammatory cytokines; Leukocytes; Neurodestruction; Neurological deficits; Neuroprotection; P38 mitogen activated protein kinase; Thromboembolic stroke; TNF

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; ANTIINFLAMMATORY AGENT; CALCIUM ION; CELL ADHESION MOLECULE; CHEMOKINE; CHLORIDE ION; CYTOKINE; DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; METHYLXANTHINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE SYNTHASE; POTASSIUM ION; SB 269063; SODIUM ION; SUPEROXIDE DISMUTASE; SYNAPTOPHYSIN; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN INJURY; BRAIN ISCHEMIA; CELL INFILTRATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; ENCEPHALITIS; ENZYME ACTIVATION; HUMAN; INFLAMMATION; MONOCYTE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; RAT; RECEPTOR UPREGULATION; REVIEW; STROKE; TISSUE INJURY;

EID: 0033810404     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.10.2281     Document Type: Review

References (221)

1. Rising stroke rates spur efforts to identify risks, prevent disease
2. Further evolution toward effective therapy for acute ischaemic stroke
3. Public perception of stroke warning signs and knowledge of potential risk factors
4. Pathophysiology and treatment of focal ischaemia. Part I: Pathophysiology
5. Pathophysiology and treatment of focal cerebral ischaemia
6. Emerging treatments for stroke in humans
7. New and investigational treatment options for ischaemic stroke
8. NMDA antagonists for stroke and head trauma: Current status
9. Glycine site antagonists and stroke
10. Calcium channel blockers in cerebral ischaemia
11. Macrophages and the nervous system
12. Quantitative aspects of reactive gliosis: A review
13. Assessment of neurotoxicity: Use of glial fibrillary acidic protein as a biomarker
14. Reactive gliosis
15. Regulation of glial intermediate filaments in astrogliosis
16. Gliosis following CNS injury: The anatomy of astrocytic scars and their influences on axonal elongation
17. Interleukin-1 injection into mammalian brain stimulates astrogliosis and neovascularization
18. Influences of glial environment on the elongation of axons after injury: Transplantation studies in adult rodents
19. Long-term degeneration renders central tracts refractory to penetration by regenerating optic fibres
20. Interleukin-1 of the central nervous system is produced by ameboid microglia
21. Production of tumour necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus
22. Production of tumour necrosis factor-α by microglia and astrocytes in culture
23. Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines
24. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumour necrosis factor
25. Localisation of TNF-α and IL-1β immunoreactivities in striatal neurons after surgical injury to hippocampus
26. Tumour necrosis factor identified in multiple-sclerosis brain
27. Microglial interleukin-1β expression in human head injury: Correlation with neuronal and neuritic β-amyloid precursor protein expression
28. Immunofluorescence studies of the monocytes in the injured rat brain
29. The role of mononuclear phagocytes in wound healing after traumatic injury to the adult mammalian brain
30. Cerebral infarction: Evolution of histopathological changes after occlusion of a middle cerebral artery in primates
31. Imaging of leukocytic infiltration in human cerebral infarcts
32. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period
33. Neutropenia reduces the volume of cerebral infarct after transient middle cerebral artery occlusion in the rat
34. Focal cerebral ischaemia in the rat: Temporal profile of neutrophil responses
35. Development of tissue damage, inflammation and resolution following stroke: An immunohistochemical and quantitative planimetric study
36. Reperfusion following focal stroke hastens inflammation and resolution of ischaemic injury
37. Temporal profile of ischaemic tissue damage, neutrophil response and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat
38. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke
39. Reperfusion increases neutrophils and LTB4 receptor binding in rat focal ischaemia
40. Polymorphonuclear leukocyte infiltration into cerebral focal ischaemic tissue: Myeloperoxidase activity assay and histologic verification
41. Influence of granulocytopenia on canine cerebral ischaemia induced by an embolism
42. Inflammatory mediators and stroke: New opportunities for novel therapeutics
43. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischaemia and stroke
44. Inflammation of the brain after ischaemia
45. Background review and current concepts of reperfusion injury
46. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons
47. Granulocyte adhesion, deformability and super oxide formation in acute stroke
48. Cytokines and endothelial cell biology
49. Tumour necrosis factor, other cytokines and disease
50. Characterization of TNF receptors
51. Tumour necrosis factor-α in stroke and neurotrauma
52. Effects of kainic acid on messenger RNA levels of IL-1β, IL-6, TNF-α and LIF in the rat brain
53. Release of proinflammatory and prothrombotic mediators in the brain and peripheral circulation in spontaneously hypertensive and normotensive Wistar-Kyoto rats
54. Effect of neurotoxic lesion in histaminergic neurons on brain tumour necrosis factor levels
55. Closed head injury triggers early production of TNF-α and IL-6 by brain tissue
56. Experimental traumatic brain injury induces expression of TNF-α-mRNA in the CNS
57. Increase in IL-6 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro54866, a peripheral-type (p site) ligand
58. Elevation of tumour necrosis factor in head injury
59. Tumour necrosis factor-α expression in ischaemic neurons
60. Concomitant cortical expression of TNF-α and IL-1β mRNA following transient focal ischaemia
61. Expression of tumour necrosis factor-α after focal cerebral ischaemia in the rat
62. Tumour necrosis factor-α: A mediator of focal ischaemic brain injury
63. Functions and mechanism of interleukin-1 in the brain
64. Biology of interleukin-1
65. Interleukin-1 receptors in mouse brain: Characterization and neuronal localisation
66. Brain interleukin-1 expression induced by peripheral lipopolysaccharide administration
67. Peripheral lipopolysaccharide stimulations induces interleukin-1β mRNA in rat brain microglial cells
68. Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: Evidence of a role for microglia in cytokine production
69. Experimental brain injury induces expression of interleukin-1β messenger RNA in the rat brain
70. Induction of interleukin-1β mRNA in rat brain after transient forebrain ischaemia
71. An in situ hybridisation study on interleukin-1β mRNA induced by transient forebrain ischaemia in the rat brain
72. Interleukin-1 as a pathogenetic mediator of ischaemic brain damage in the rats
73. Interleukin-1β mRNA expression in ischaemic rat cortex
74. Induction of interleukin-1β mRNA after focal cerebral ischaemia in the rat
75. Biological basis for interleukin-1 in disease
76. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat
77. Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovas
78. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia
79. Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat
80. Attenuation of stroke in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain
81. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischaemia in the rat
82. Interleukin-1 stimulates the expression of Type I and Type II interleukin-1 receptors in the rat insulinoma cell line Rinm5F; sequencing a rat Type II interleukin-1 receptor cDNA
83. An mRNA homologous to interleukin-1 receptor Type I is expressed in cultured rat sympathetic ganglia
84. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types
85. CDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily
86. The two interleukin-1 receptors play different roles in IL-1 actions
87. In situ histochemical localisation of Type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary and adrenal gland of the mouse
88. Localisation of interleukin 1 type receptor mRNA in rat brain
89. Interleukin-1 receptor Type I mRNA in mouse brain as affected by peripheral administration of bacterial lipopolysaccharide
90. Increased interleukin-1 receptor and receptor antagonist gene expression after focal stroke
91. Monocyte adherence to human vascular endothelium
92. Leukocyte-endothelial cell adhesion induced by ischaemia and reperfusion
93. Upregulation of intracellular adhesion molecule-1 (ICAM-1) on brain microvascular endothelial cells in rat ischaemic cortex
94. Demonstration of increased endothelial-leukocyte adhesion molecule 1 mRNA expression in rat ischaemic cortex
95. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischaemia and reperfusion
96. Expression of immediate early gene and growth factor mRNAs in a focal cerebral ischaemia model in the rat
97. 70 kDa heat shock protein and c-fos gene expression after transient ischaemia
98. Focal ischaemia in rats causes time-dependent expression of c-fos protein immunoreactivity in widespread regions of ipsilateral cortex
99. Expression of interleukin-6, c-fos and zif268 mRNA in rat ischaemic cortex
100. Regional expression of heat shock protein 70 mRNA and c-fos mRNA following focal ischaemia in rat brain
101. Cytokine-induced neutrophil chemoattractant mRNA expressed in cerebral ischaemia
102. Interferon inducible protein 10 in ischaemic cortex: Regulation and chemokine function
103. Monocyte chemoattractant protein-1 (MCP-1) mRNA expression in rat ischaemic cortex
104. P53-immunoreactive protein and p53 mRNA expression after transient middle cerebral artery occlusion in rats
105. Proteolytic cascade enzymes increase in focal cerebral ischaemia in rat
106. Matrix metalloproteinase expression increases following cerebral focal ischaemia: Inhibition of MMP-9 reduces infarct size
107. Subtractive cloning identifies tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) increased gene expression in focal stroke
108. Transforming growth factor-β1 exhibits delayed gene expression following focal ischaemia
109. Delayed expression of osteopontin after focal stroke in the rat
110. Osteopontin and its integrin receptor avb3 are upregulated during formation of the glial scar following focal stroke
111. Inhibition of tumour necrosis factor-alpha (TNF-α) activity in rat brain is associated with cerebroprotection after closed head injury
112. Inhibition of tumour necrosis factor and amelioration of brain infarction in mice
113. Neuroprotective effects of TNF binding protein in focal cerebral ischaemia
114. Inhibition of tumour necrosis factor-alpha reduces focal cerebral ischaemic injury in the spontaneously hypertensive rat
115. Endogenous tumour necrosis factor, interleukin-6 and gamma interferon levels during Listeria monocytogenes infection in mice
116. Generation and characterization of hamster monoclonal antibodies that neutralise murine tumour necrosis factors
117. An antibody to Lymphotoxin and tumour necrosis factor prevents transfer of experimental allergic encephalomyelitis
118. Two tumour necrosis binding proteins purified from human urine; evidence for immunological cross-reactivity with cell surface tumour necrosis factor receptors
119. Molecular cloning and expression of a receptor for human tumour necrosis factor
120. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumour necrosis factor receptor I
121. Inhibition of tumour necrosis factor is protective against neurologic dysfunction after active immunisation of Lewis rats with myelin basic protein
122. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
123. Thrombin activates nuclear factor-κβ and potentiates endothelial cell activation by TNF
124. Motor neuron cell death in wobbler mutant mice follows overexpression of the G-protein-coupled, protease-activated receptor for thrombin
125. Regulation of neurons and astrocytes by thrombin and protease nexin-1. Relationship to brain injury
126. Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities
127. Neurotoxic components in normal serum
128. Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines
129. 2+ accumulation
130. Tumour necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis
131. Tumour necrosis factor facilitates regeneration of injured central nervous system axons
132. Tumour necrosis factor: A pleotropic cytokine and therapeutic target
133. Altered neuronal and microglial responses to excitotoxic and ischaemic brain injury in mice lacking TNF receptors
134. Brain TNF: Damage limitation or damaged reputation?
135. Induction of tolerance to ischaemia by preconditioned interleukin-1a in gerbil hippocampal neurons
136. Tumour necrosis factor-alpha augments pulmonary arterial transendothelial albumen flux in vitro
137. Cachectin: More than a tumour necrosis factor
138. Modulation of blood-brain barrier permeability by tumour necrosis factor and antibody to tumour necrosis factor in the rat
139. Tumour necrosis factor-α-induced gelatinase B causes delayed opening of the blood brain barrier: An expanded therapeutic window
140. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes
141. Tumour necrosis factor mediates myelin and oligodendrocyte damage in vitro
142. Stroke risk factors prepare brainstem tissues for modified local Shwartzman reaction
143. Genetic hypertension and increased susceptibility to cerebral ischaemia
144. Interleukins and tumour necrosis factor in inflammation
145. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumour necrosis factor
146. Capillary plugging by granulocytes and the no-reflow phenomenon in the microcirculation
147. Cytokines and reperfusion in ischaemic stroke
148. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc
149. Anti-CD11b monoclonal antibody reduces ischaemic cell damage after transient focal cerebral ischaemia in rat
150. Anti-ICAM-1 antibody reduces ischaemic cell damage after transient middle cerebral artery occlusion in the rat
151. Post ischaemic administration of an anti-MAC-1 antibody reduces ischaemic cell damage after transient middle cerebral artery occlusion in the rat
152. Anti-CDIIb monoclonal antibody reduces ischaemic cell damage after transient (2h) but not after permanent MCA occlusion in the rat
153. Monoclonal antibody to ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model
154. Reduction of central nervous system ischaemic injury by monoclonal antibody to intercellular adhesion molecule
155. Anti-Intercellular adhesion molecule-1 antibody reduces ischaemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat
156. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischaemia in baboons
157. Correlation between myeloperoxidose-quantified neutrophil accumulation and ischaemic brain injury in the rat: Effects of neutrophil depletion
158. Neutrophil as a mediator of ischaemic edema formation in the brain
159. Leukocyte involvement in cerebral infarct generation after ischaemia and reperfusion
160. Monoclonal antibodies preventing leukocyte activation reduce experimental neurological injury and enhance efficacy of thrombolytic therapy
161. The role of neutrophils and platelets in a rabbit model of thromboembolic stroke
162. Leukocyte involvement in cerebral ischaemia and reperfusion injury
163. Experimental antileukocyte interventions in cerebral ischaemia
164. Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischaemia in the rat
165. The specific Type IV phosphodiesterase inhibitor rolipram suppresses tumour necrosis factor-α production by human mononuclear cells
166. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C
167. Protein kinase C regulates TNF-α production by human monocytes
168. Poly(A) removal is the kinase regulated step in tumour necrosis factor mRNA decay
169. Tumour necrosis factor increases stability of Interleukin-1 mRNA by activating protein kinase C
170. Staurosporine encapsulated into pH-sensitive liposomes reduces TNF production and increases survival in rat endotoxin shock
171. Protein kinase C: Is its pivotal role in cellular activation over-stated?
172. Neurotrophic molecules: Strategies for designing effective therapeutic molecules in neurodegeneration
173. Sounding the alarm: Protein kinase cascades activated by stress and inflammation
174. Mitogen-activated protein kinase pathways
175. P38 MAP kinases: Beyond the stress response
176. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase
177. Bicyclic imidazoles as a novel class of cytokine synthesis inhibitors
178. The role of the MAP kinase homologue, CSBP in LPS and cytokine signaling
179. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
180. An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultures cerebellar granule neurons
181. Inhibitors of p38 mitogen-activated protein kinase promote neuronal survival in vitro
182. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway
183. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene
184. Withdrawal of survival factors results in activation of JNK pathway in neuronal cells leading to Fas ligand induction and cell death
185. Inhibition of p38 mitogen-activated protein kinase by insulin in cultured fetal neurons
186. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells
187. Activation of p38 MAPK in microglia after ischemia
188. Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level
189. Inhibition of interleukin-1 (IL-1) and tumour necrosis factor (TNF) production by pryridinyl imidazole compounds is independent of cAMP elevating mechanisms
190. 1-Substituted 4-aryl-5-pridinylimidozoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency
191. Pyridinyl imidazole inhibitors of p38 MAP kinase bind in the ATP site
192. Identification and characterization of a novel protein kinase involved in the regulation of inflammatory cytokine biosynthesis
193. Novel homologues of CSBP/p38 MAP kinase: Activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem
194. Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages lipopolysaccharide and interferon-gamma
195. SB 203580 inhibits cytokine suppressive binding protein/p38 kinase, nitric oxide production and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes
196. Cytokine induction of inducible nitric oxide synthase in an oligodendrocyte cell line: Role of p38 mitogen-activated protein kinase activation
197. Erk and p38 subgroups of MAP kinases regulate inducible nitric oxide synthase and TNF-α gene expression in endotoxin-stimulated primary glial cultures
198. P38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol
199. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways
200. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA
201. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor
202. Stress-activated protein kinase/Jun N-terminal kinase is required for interleukin (IL)-1-induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB
203. Cooling and rewarming-induced IL-8 expression in human bronchial epithelial cells through p38 MAP kinase-dependent pathway
204. Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase
205. Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins
206. Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase 2
207. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes
208. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
209. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1
210. Differential activation of MAPK/ERK and p38/SAPK in neurons and glia following focal cerebral ischemia in the rat
211. Selective inhibition of p38 mitogen activated kinase reduces brain injury and neurological deficits in rat focal stroke models
212. Innate and adaptive immune responses can be beneficial for CNS repair
213. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy
214. The ability of human schwann cell grafts to promote regeneration in the transected nude rat spinal cord
215. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor
216. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion
217. Inflammation after axonal injury has conflicting consequences for recovery of function: Rescue of spared axons is impaired but regeneration is supported
218. Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein
219. TNF-alpha activates at least two apoptotic signaling cascades
220. Induction of apoptosis signal regulating kinase 1 (ASK1) after spinal cord injury in rats: Possible involvement of ASK1-JNK and p38 pathways in neuronal apoptosis
221. P38 kinase is activated in the Alzheimer's disease brain